- ►annals.org [PDF] B Zinman, BJ Hoogwerf, S Duran Garcia, DR … - Annals of internal medicine, 2007 - Am Coll Physicians Background: Exenatide therapy is effective in combination with metformin or
sulfonylureas for treating type 2 diabetes. Thiazo- lidinediones (TZDs) also are
commonly used, but the efficacy of exenatide with a TZD has not been reported. Cited by 119 - Related articles - BL Direct - All 5 versions
MA Nauck, S Duran, D Kim, D Johns, J … - Diabetologia, 2007 - Springer Abstract Aims/hypothesis The aim of this 52-week, open-label, non- inferiority
trial was to compare the safety and efficacy of exenatide (an incretin mimetic)
with that of biphasic insulin aspart. Materials and methods Patients on ... Cited by 132 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org D Kim, L MacConell, D Zhuang, PA Kothare, … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—From baseline to week 15, exenatide LAR reduced mean ± SE A1C by
−1.4 ± 0.3% (0.8 mg) and −1.7 ± 0.3% (2.0 mg), compared with +0.4 ± 0.3%
with placebo LAR (P < 0.0001 for both). A1C of ≤7% was achieved by 36 and ... Cited by 127 - Related articles - BL Direct - All 5 versions
DC Klonoff, JB Buse, LL Nielsen, X Guan, … - Current Medical Research and Opinion®, 2007 - informahealthcare.com Background: Exenatide, an incretin mimetic for adjunctive treatment of type 2
diabetes (T2DM), reduced hemoglobin A1c (A1C) and weight in clinical trials. The
objective of this study was to evaluate the effects of ≥3 years exenatide ... Cited by 91 - Related articles - BL Direct - All 7 versions
JB Buse, DC Klonoff, LL Nielsen, X Guan, … - Clinical therapeutics, 2007 - Elsevier For this interim analysis, data were pooled from patients who completed 1 of
three 30-week, multicenter, double-blind, placebo-controlled trials and their
open-label extensions. In the initial trials, subjects were randomized to ... Cited by 91 - Related articles - All 3 versions
- ►annals.org [PDF] RJ Heine, LF Van Gaal, D Johns, MJ Mihm, … - Annals of internal medicine, 2005 - Am Coll Physicians Patients: 551 patients with type 2 diabetes and inadequate gly- cemic control
(defined as hemoglobin A1c level ranging from 7.0% to 10.0%) despite combination
metformin and sulfonylurea therapy. Intervention: Exenatide, 10 g twice ... Cited by 329 - Related articles - BL Direct - All 7 versions
L Blonde, EJ Klein, J Han, B Zhang, SM Mac, … - Diabetes, Obesity & Metabolism, 2006 - pt.wkhealth.com Results: Patients completed 82 weeks of exenatide treatment [n = 314, 63% M, age
56 ± 10 years, weight 99 ± 21 kg, body mass index 34 ± 6 kg/m 2 , A1C 8.3 ±
1.0% (mean ± SD)]. Reduction in A1C from baseline to week 30 [-0.9 ± 0.1% ... Cited by 172 - Related articles - BL Direct - All 6 versions
V Fonseca, A Schweizer, D Albrecht, MA … - Diabetologia, 2007 - Springer Abstract Aims/hypothesis Type 2 diabetes is difficult to manage in patients with
a long history of disease requiring insulin therapy. Moreover, addition of most
currently available oral antidiabetic agents increases the risk of ... Cited by 104 - Related articles - BL Direct - All 4 versions
T Vilsbøll, M Zdravkovic, T Le-Thi, T Krarup, … - Diabetes Care, 2007 - Am Diabetes Assoc Main inclusion criteria were patients aged ≥18 years with type 2 diabetes and
A1C ≥7.5 and ≤10.0% (diet) or ≥7.0 and ≤9.5% (mono–oral antidiabetes
drug); previous therapy was discontinued. Fasting plasma glucose (FPG) at ... Cited by 116 - Related articles - BL Direct - All 5 versions
- ►wanfang.gov.tw [DOC] RE Amori, J Lau, AG Pittas - Jama, 2007 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 240 - Related articles - BL Direct - All 8 versions
